A5089954905- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Respiratory and Cough-Related Research
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Voice and Speech Disorders
- Cancer, Hypoxia, and Metabolism
- Asthma and respiratory diseases
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer survivorship and care
- Cancer Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Neuroblastoma Research and Treatments
- Metastasis and carcinoma case studies
University of Manchester
2016-2025
The Christie NHS Foundation Trust
2016-2025
National Health Service
2014-2025
Cancer Research UK Manchester Institute
2016-2025
Cancer Research UK
2016-2025
CRUK Lung Cancer Centre of Excellence
2016-2025
The Christie Hospital
2014-2024
Centre for Cancer Biology
2024
Cancer Research UK Manchester Centre
2011-2023
Manchester Academic Health Science Centre
2011-2021
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine inhibitor targeting ALK. Whether crizotinib is superior standard chemotherapy respect efficacy unknown.
The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.We conducted an open-label, phase 3 trial comparing in 343 patients nonsquamous NSCLC who had received no previous systemic disease. Patients were randomly assigned to receive oral at a dose 250 mg twice daily or intravenous (pemetrexed, 500 per square meter body-surface area, plus either cisplatin, 75 meter,...
Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and genome evolution have been limited to small retrospective cohorts. We wanted prospectively investigate in relation clinical outcome determine the clonal nature of driver events evolutionary processes early-stage NSCLC.
Lung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be provide prognostic information and/or early indication patient response conventional therapy.In this single-center prospective study, blood samples for CTC analysis were obtained from 101 previously untreated,...
Purpose Circulating tumor cells (CTCs) may have utility as surrogate biomarkers and “virtual” biopsies. We report the clinical significance molecular characteristics of CTCs CTC clusters, termed circulating microemboli (CTM), detected in patients with small-cell lung cancer (SCLC) undergoing standard treatment. Patients Methods Serial blood samples from 97 receiving chemotherapy were analyzed using EpCam-based immunomagnetic detection a filtration-based technique. Proliferation status (Ki67)...
Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm) and T790M resistance mutations. AURA (NCT01802632) a phase I/II clinical trial to determine the dose, safety, efficacy of osimertinib. This article reports results from II extension component. Patients Methods with EGFR-TKI–pretreated EGFRm- T790M-positive advanced non–small-cell lung cancer (NSCLC) received once-daily osimertinib 80...
BackgroundConcurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but optimal radiotherapy schedule and dose remains controversial. The aim this study was to establish a treatment regimen cancer.MethodsThe CONVERT trial an open-label, phase 3, randomised superiority trial. We enrolled adult patients (aged ≥18 years) who had cytologically or histologically confirmed Eastern Cooperative Oncology Group performance status 0–2, adequate pulmonary function....
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results. Patients and Methods were randomly assigned to receive oral 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m2 plus cisplatin 75 carboplatin (area under concentration-time curve of 5 6 mg·mL/min) every 3 weeks for a...
<h3>Importance</h3> There are no specifically approved targeted therapies for the most common genomically defined subset of non–small cell lung cancer (NSCLC),<i>KRAS</i>-mutant cancer. <h3>Objective</h3> To compare efficacy mitogen-activated protein kinase (MEK) inhibitor selumetinib + docetaxel with alone as a second-line therapy advanced<i>KRAS</i>-mutant NSCLC. <h3>Design, Setting, and Participants</h3> Multinational, randomized clinical trial conducted at 202 sites across 25 countries...
Abstract Purpose: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom. AZD3965 proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis. We investigated therapeutic potential of small cell lung cancer (SCLC) seeking rationale for clinical testing this disease and putative predictive biomarkers trial use. Experimental Design: sensitivity was determined seven SCLC lines, normoxia hypoxia, a xenograft...
Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal signaling. This randomized, placebo-controlled phase III study assessed the efficacy vandetanib plus pemetrexed as second-line therapy in advanced non-small-cell lung cancer.Patients (N = 534) were randomly assigned to receive 100 mg/d 500 mg/m(2) every 21 days (n 256) or placebo 278). Progression-free survival (PFS) was primary end point; overall survival, objective response rate, disease...
This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients advanced non-small-cell lung cancer (NSCLC).
Recent advances in technology now permit robust and reproducible detection of circulating tumour cells (CTCs) from a simple blood test. Standardization methodology has been instrumental facilitating multicentre trials with the purpose evaluating clinical utility CTCs. We review current body evidence supporting prognostic value CTC enumeration breast, prostate colorectal cancer, using standardized approaches, studies correlation number radiological outcome. The exploitation CTCs cancer...
To evaluate the efficacy and safety of dulanermin combined with paclitaxel carboplatin (PC) bevacizumab (PCB) as first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC).Patients squamous NSCLC and/or CNS metastases received PC every 3 weeks alone (arm 1) 8 mg/kg 5 days 2). Patients nonsquamous PCB 3) 4) 20 2 5). The primary end point was objective response rate (ORR).Overall, 213 patients were randomly assigned 1, n = 41; arm 2, 39; 3, 42; 4, 40; 5, 41). ORR in arms...
Purpose Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study ALK-positive non–small-cell lung cancer. Patients and Methods were randomly assigned to receive (250 mg twice daily; n = 172) or (pemetrexed 500 mg/m 2 plus cisplatin 75 carboplatin at area under curve 5 6, every 3 weeks for ≤ six cycles; 171). with stable treated brain metastases (tBM) eligible. assessed baseline 6 12 patients without known (BM),...